Regional leaders seem like a mix of good and bad. But the worst micromanagement in this industry always starts at the top. So the real question is what is the mentality of top management above the Salesforce? It's a bit of a roll of the dice with a new company, there is no track record, and the pressure for revenue is on. Could end up horrible, could end up great and rewarding. Only time will tell.
Welcome to the glorious world of start ups. They are perfect when you are without a job (or losing one soon) Otherwise they are always a high risk /high reward gamble. Theres a little more certainty if you are following former colleagues.
Its just the nature of the beast.
Based on the reduction in the PANSS scores in the studies, this is a mediocre medication at best. The high percentage of sedation is also not positive.
When it gets closer to 1/15, I’m going to ask for more money. I don’t think they’ve considered most of us will be getting some sort of merit increase by March.
If they just don’t care about the lower than promised offers, there will be several backing out. Also what about the 2nd hiring wave that they will be in a hurry to complete? Lower than $130k just wont net the type of experience they need.
Most experienced reps at Otsuka, Janssen and Alkermes are not making more than $130k. Don't let
anyone here fool you with that BS. This is psychiatry, not oncology. Any dumbass can sell in psychiatry.
Just look at the people in the 3 companies I mentioned.
Most experienced reps at Otsuka, Janssen and Alkermes are not making more than $130k. Don't let
anyone here fool you with that BS. This is psychiatry, not oncology. Any dumbass can sell in psychiatry.
Just look at the people in the 3 companies I mentioned.
That’s right. It’s going to be a very tough sell. The sedation will be a problem. The lower EPS may help a few patients more, but the vast majority of patients never experience severe EPS, or even bad enough to switch to another product. As usual, the managed care coverage will be the biggest problem of all.
Most experienced reps at Otsuka, Janssen and Alkermes are not making more than $130k. Don't let
anyone here fool you with that BS. This is psychiatry, not oncology. Any dumbass can sell in psychiatry.
Just look at the people in the 3 companies I mentioned.
Will Medicaid cover this drug? That’s the question. With the majority of patients covered on state Medicaid plans...what’s ITC’s strategy? I know my state waits a year to even consider a new to market drug.
Based on the reduction in the PANSS scores in the studies, this is a mediocre medication at best. The high percentage of sedation is also not positive.
you think schizophrenia is the target here? Really?
Of the branded market, who’s talking Schiz? Anyone? Not even Vanda with Fanapt and that’s their only indication. They’re off label with anxiety. Allergen - every patient is bipolar. Sunovion- they’ll take what they get. Otsuka- PTSD and anxiety.
the real push early is relationships and then bipolar into MDD. CMHC’s, beholdin to Medicaid, stay with the cheap stuff. Period
and funny you think sedation is bad. Quetiapine has done a multi-million dollar business on sedation alone.
you think schizophrenia is the target here? Really?
Of the branded market, who’s talking Schiz? Anyone? Not even Vanda with Fanapt and that’s their only indication. They’re off label with anxiety. Allergen - every patient is bipolar. Sunovion- they’ll take what they get. Otsuka- PTSD and anxiety.
the real push early is relationships and then bipolar into MDD. CMHC’s, beholdin to Medicaid, stay with the cheap stuff. Period
and funny you think sedation is bad. Quetiapine has done a multi-million dollar business on sedation alone.
I tried to negotiate salary and some sort of sign on bonus. Nothing for me.For those of you already hired in Round one, any feedback re ability to negotiate anything - salary, vacation, new hire bonus. I’m in round two. Thanks.
For those of you already hired in Round one, any feedback re ability to negotiate anything - salary, vacation, new hire bonus. I’m in round two. Thanks.
I had an opportunity to throw my hat in the ring for one of these openings, but I ultimately decided to sit this one out. Coming to market with only a schizophrenia indication relegates much of your selling to community mental health clinics, as mentioned above. A novel mechanism will certainly raise some eyebrows but the majority of the end users are not being treated in a private practice setting and are a heavily subsidized patient population. In my state, all of the managed medicaid plans require a minimum of two generic atypicals before they will even consider covering a branded agent with a prior auth. In that regard, Caplyta will just be the next branded agent on the non-preferred list. An additional indication for bipolar is the game-changer. Unless you are going to sell this product with a wink and a nod to private psychs under the umbrella of “class effect” efficacy in bipolar folks....it’s going to be a bit of a slog in the early stages of launch. Best wishes to you anyway.
